INTERNATIONAL ISSUES IN UROLOGIC ONCOLOGY

Conference Co-Chairs | Nathan Lawrentschuk, MD and Laurence Klotz, MD
ROOM AUDITORIUM VII

WELCOME & INTRODUCTIONS
7:00  Meet and Greet International Colleagues (coffee and refreshments served)
7:30  Co-Chairmen’s Welcome & Framing of Theme | Laurence Klotz & Nathan Lawrentschuk

7:35-8:45  SESSION ONE | PROSTATE CANCER-LOCALIZED | Co-Moderators: Mark Frydenberg & Francisco Botelho
1  The USPSTF Screening Review—What are the Implications? | Matthew Cooperberg, MD
2  Focal Therapy for Prostate Cancer - Who and How? | Rafael Sanchez-Salas, MD
3  Active Surveillance: Biopsy vs MRI for Follow Up | Arnauld Villers, MD
4  Advanced Risk Modeling for Prostate Cancer | Boris Hadaschik, MD
5  DNA Repair Mutations and Prostate Cancer | Marc Dall’Era, MD
6  DISCUSSION

8:50-9:50  SESSION TWO | KIDNEY CANCER | Co-Moderators: Arnaldo Figueiredo & Peter Mulders
7  Renal Tumor Anatomic Complexity: Clinical Implications for Urologists | Robert Uzzo, MD
8  Management of Complex Renal Masses: Risk Benefit Trade-Off of Partial vs Radical Nephrectomy | Alessandro Voïpe, MD
9  Cytoreductive Surgery for RCC | Makarand Khochikar, MD
10  Variation in Surgical Quality Affects Outcome of RCC Treatment | Antonio.Finelli, MD
11  DISCUSSION

9:50-11:00  SESSION THREE | PROSTATE CANCER: ADVANCED | Co-Moderators: Nathan Lawrentschuk & Fernando M Calais da Silva
12  Prostate Cancer Stem Cells | Ricardo Leão, MD
13  Local Treatment for Metastatic Prostate Cancer | Derya Tilki, MD
14  CV Disease and ADT | Jehonathan Pinthus, MD
15  Bone Targeted Treatment in Advanced Prostate Cancer | Fred Saad, MD
16  Radiogenomics, MRI & Prostate Cancer Imaging | Robert Reiter, MD
17  DISCUSSION

11:00-11:45  SESSION FOUR | BLADDER CANCER | Co-Moderators: Peter Black & Badrinath Konety
18  Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer | Seth Lerner, MD
19  Neoadjuvant Chemo - When, What and Why? | Badrinath Konety, MD
20  Can Genetic Analysis in Bladder Cancer Enhance Decision Making? | Peter Black, MD
21  DISCUSSION

11:45  WORKING LUNCH
Complimentary to All Seated Participants Attending Session Four Working Lunch

12:00-12:45  SESSION FIVE | MAJOR OBSERVATIONS | Co-Moderators: Laurence Klotz, Peter Hammerer
22  Observation #1 | Prostate-Specific Membrane Antigen-Radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer | Markus Graefen, MD
23  Observation #2 | Oligometastatic Bone Disease in Prostate Cancer Patients Treated on the TROG 03.04 RADAR Trial | Shin Egawa, MD
24  Observation #3 | The Unmet Need in Locally Advanced RCC Treatment: Game Changers? | Peter Mulders, MD
25  DISCUSSION

12:45  ADJOURN